Monitoring metrics over time: Why clinical trialists need to systematically collect site performance metrics.

Victoria Yorke-Edwards, Carlos Diaz-Montana, Macey L Murray, Matthew R Sydes, Sharon B Love
Author Information
  1. Victoria Yorke-Edwards: MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. ORCID
  2. Carlos Diaz-Montana: MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. ORCID
  3. Macey L Murray: MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. ORCID
  4. Matthew R Sydes: MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. ORCID
  5. Sharon B Love: MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. ORCID

Abstract

Background: Over the last decade, there has been an increasing interest in risk-based monitoring (RBM) in clinical trials, resulting in a number of guidelines from regulators and its inclusion in ICH GCP. However, there is a lack of detail on how to approach RBM from a practical perspective, and insufficient understanding of best practice.
Purpose: We present a method for clinical trials units to track their metrics within clinical trials using descriptive statistics and visualisations.
Research Design: We suggest descriptive statistics and visualisations within a SWAT methodology.
Study Sample: We illustrate this method using the metrics from TEMPER, a monitoring study carried out in three trials at the MRC Clinical Trials Unit at UCL.
Data Collection: The data collection for TEMPER is described in .
Results: We show the results and discuss a protocol for a Study-Within-A-Trial (SWAT 167) for those wishing to use the method.
Conclusions: The potential benefits metric tracking brings to clinical trials include enhanced assessment of sites for potential corrective action, improved evaluation and contextualisation of the influence of metrics and their thresholds, and the establishment of best practice in RBM. The standardisation of the collection of such monitoring data would benefit both individual trials and the clinical trials community.

Keywords

References

  1. PLoS One. 2012;7(12):e51623 [PMID: 23251597]
  2. Ther Innov Regul Sci. 2021 Jul;55(4):899-906 [PMID: 33914298]
  3. Contemp Clin Trials. 2016 Nov;51:15-27 [PMID: 27641969]
  4. Clin Trials. 2017 Dec;14(6):584-596 [PMID: 28786330]
  5. Clin Trials. 2021 Apr;18(2):158-167 [PMID: 33258688]
  6. Trials. 2018 Oct 16;19(1):562 [PMID: 30326948]
  7. Ther Innov Regul Sci. 2014 Nov;48(6):671-680 [PMID: 30227471]
  8. Trials. 2018 Oct 16;19(1):557 [PMID: 30326967]
  9. Clin Trials. 2020 Feb;17(1):3-14 [PMID: 31647325]
  10. Clin Trials. 2019 Oct;16(5):502-511 [PMID: 31347385]
  11. Br J Clin Pharmacol. 2019 Dec;85(12):2784-2792 [PMID: 31471967]
  12. Trials. 2018 Feb 23;19(1):139 [PMID: 29475444]
  13. Trials. 2019 Apr 17;20(1):227 [PMID: 30995932]
  14. Contemp Clin Trials. 2021 Apr;103:106290 [PMID: 33503495]
  15. Clin Trials. 2018 Dec;15(6):600-609 [PMID: 30132361]

Grants

  1. MC_EX_UU_G0800814/Medical Research Council
  2. MC_UU_00004/08/Medical Research Council
  3. MC_UU_12023/24/Medical Research Council

Word Cloud

Created with Highcharts 10.0.0trialsclinicalmonitoringmetricsRBMmethodSWATbestpracticewithinusingdescriptivestatisticsvisualisationsTEMPERdatacollectionStudy-Within-A-TrialpotentialBackground:lastdecadeincreasinginterestrisk-basedresultingnumberguidelinesregulatorsinclusionICHGCPHoweverlackdetailapproachpracticalperspectiveinsufficientunderstandingPurpose:presentunitstrackResearchDesign:suggestmethodologyStudySample:illustratestudycarriedthreeMRCClinicalTrialsUnitUCLDataCollection:describedResults:showresultsdiscussprotocol167wishinguseConclusions:benefitsmetrictrackingbringsincludeenhancedassessmentsitescorrectiveactionimprovedevaluationcontextualisationinfluencethresholdsestablishmentstandardisationbenefitindividualcommunityMonitoringtime:trialistsneedsystematicallycollectsiteperformanceRisk-basedcentralcentralised

Similar Articles

Cited By